Review of hormonal treatment of breast cancer

Nigerian Journal of Clinical Practice

Volumn 15, Issue 1, 2012, Pages 9-14

  Abdulkareem, I H ^a   Zurmi, I B ^a  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Breast cancer; Estrogen; Hormones; Progesterone

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST TUMOR; DRUG EFFECT; FEMALE; GENETICS; HUMAN; PROTO ONCOGENE; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENES, ERBB-2; HUMANS; RECEPTORS, ESTROGEN;

EID: 84861617933     PISSN: 11193077     EISSN: None     Source Type: Journal    
DOI: 10.4103/1119-3077.94088     Document Type: Review

References (47)

1. Águas F, Martins A, Gomes TP, Sousa MD, Silva DP. Prophylaxis approach to a-symptomatic post-menopausal women: Breast cancer. Maturitas 2005;52(Suppl1):23-31.
2. Weinberg OK, Marquez-Garban DC, Pietras RJ. New approaches to reverse resistance to hormonal therapy in human breast cancer. Drug Resist Updates 2005;8:219-33.
3. Dumitrescu RG, Cotarla I. Understanding breast cancer risk: Where do we stand in. 2005-J Cell Mole Med 2005. 9. 208-21
4. Russell RC, et al. Bailey and Love's short practice of surgery. In Chapter on breast cancer. 23rd ed. London: Arnold; 2000.
5. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study. J Nat Cancer Inst 1998;90:1371-88.
6. Singh RR, Kumar R. Steroid hormone receptor signaling in tumorigenesis. J Cell Biochem 2005;96:490-505.
7. Hung MC, Lau YK. Basic science of HER-2/neu: A review. Semin Oncol 1999;26(Suppl 12):51-9.
8. Gancberg D, Lespagnard L, Rouas G, Paesmans M, Piccart M, Di Leo A, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Am J Clin Pathol 2000;113:675-82.
9. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999;26(Suppl 12):78-83.
10. Sabiston DC, Lyerly HK. Sabiston textbook of surgery: The biological basis of modern surgical practice. 15th ed. Philadelphia, Pennsylvania: WB Saunders Company; 1997.
11. Kato S, Sato T, Watanabe T, Takemasa S, Masuhiro Y, Ohtake F, et al. Function of nuclear sex hormone receptors in gene regulation. Cancer Chemother Pharmacol 2005;56:4-9.
12. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004;11:643-58.
13. Lamy P-J, Verjat T, Paye M, Servanton AC, Grenier J, Leissner P, et al. NASBA: A novel approach to assess hormonal receptors and ERBB2 status in breast cancer. Clin Chem Lab Med 2005;44:3-12.
14. Malara NM, Leotta A, Sidoti A, Lio S, D'Angelo R, Caparello B, et al. Ageing, hormonal behaviour and cyclin D1 in ductal breast carcinomas. Breast 2006;15:81-9.
15. Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in late breast cancer: An early clinical appraisal of ICI46474. Br J Cancer. 1971. 25. 270-5
16. Howell A, Osborne CK, Morris C, Wakeling AE. ICI. 182,780 (Faslodex™). Cancer 2000. 89. 817-25
17. Martino S, Costantino J, McNabb M, Mershon J, Bryant K, Powles T, et al. The role of selective estrogen receptor modulators in the prevention of breast cancer: Comparison of the clinical trials. Oncologist 2004;9:116-25.
18. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999;281:2189-97.
19. Dickler MN, Norton L. The MORE trial: Multiple outcomes for raloxifene evaluation. Ann N Y Acad Sci 2001;949:134-42.
20. Cohen FJ, Watts S, Shah A, Akers R, Plouffe L. Uterine effects of. 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol 2000. 95. 104-10
21. Neven P, Quail D, Lévrier M, Aguas F, Thé HS, De Geyter C, et al. Uterine effects of estrogen plus progestin therapy and raloxifene: Adjudicated results from the EURALOX study. Obstet Gynecol 2004;103:881-91 10.
22. Barrett-Connor E, Cauley JA, Kulkarni PM, Sashegyi A, Cox DA, Geiger MJ. Risk-benefit profile for raloxifene: 4-year data from the multiple outcomes of raloxifene evaluation (MORE) randomized trial. J Bone Mineral Res 2004;19:1270-5.
23. Goss PE. Breast cancer prevention-clinical trials strategies involving aromatase inhibitors. J Steroid Biochem Mole Biol 2003;86:487-93.
24. Goss PE, Strasser-Weippl K, Brown M, Santen R, Ingle J, Bissell M. Prevention strategies with aromatase inhibitors. Clin Cancer Res 2004;10:372S-9S.
25. Brower V. Of cancer and cholesterol: Studies elucidate anticancer mechanisms of statins. J Nat Cancer Inst 2003;95:844-6.
26. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, et al. Breast cancer and nonsteroidal anti-inflammatory drugs. Cancer Res 2003;63:6096-101.
27. Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004;291:2433-40.
28. Etkind P, Sparano J. Prevention. In: Roses DF, editor. Breast cancer. Churchill Livingstone; 1999.
29. Clarke R, Skaar TC, Bouker KB, Davis N, Lee YR, Welch JN, et al. Molecular and pharmacological aspects of antiestrogen resistance. J Steroid Biochem Mole Biol 2001;76:71-84.
30. Herynk MH, Fuqua SA. Estrogen receptor mutations in human disease. Endocr Rev 2004;25:869-98.
31. Butt AJ, McNeil CM, Musgrove EA, Sutherland RL. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: The potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 2005;12(Suppl 1): S47-59.
32. Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 2004;9:95-104.
33. Gago FE, Fanelli MA, Ciocca DR. Co-expression of steroid hormone receptors (estrogen receptor [alpha] and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: Clinical outcome following tamoxifen-based adjuvant therapy. J Steroid Biochem Mole Biol 2006;98:36-40.
34. Pietras RJ, Arboleda J, Reesed D, Wongpita N, Pegram MD, Ramos L, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;10:2435-46.
35. Witters LM, Kumar R, Chinchilli VM, Lipton A. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 1997;42:1-5.
36. Kunisue H, Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, et al. Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. Br J Cancer. 1999. 82. 46-51
37. Pietras RJ. Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. Breast Jr 2003;9:361-73.
38. Borden M. In M. Borden, Editor, Current Clinical Trials: Oncology 12, Yardley, PA: MediMedia USA Inc; 2005
39. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(Suppl 4):9-15.
40. Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against her2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000;60:5887-94.
41. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa): A selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-65.
42. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/ neu cross-talk in ER/HER2-positive breast cancer. J Nat Cancer Inst 2004; 96:926-35.
43. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, et al. Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005;23:2469-76.
44. Le XF, Lammayot A, Gold D, Lu Y, Mao W, Chang T, et al. Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 2005;280:2092-104.
45. Ellis M. Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 2004;9(suppl 3):20-6.
46. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mole Cell 2001;7:673-82.
47. Peralba JM, deGraffenried L, Friedrichs W, Fulcher L, Grünwald V, Weiss G, et al. Pharmacodynamic evaluation of CCI-779: An inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003;9:2887-92.